Program overview
Context
Indication: Advanced Pancreatic Cancer
Mechanism: Unknown
Modality: Unknown
Sponsor: Zhejiang University
Timeline Staleness Signal
Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) in combination with Nivolumab
Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) in combination with Nivolumab is flagged as timeline staleness signal because public records show timeline staleness, operational burden. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 3/5
Timeline: 3/5
Recruitment burden: 2/5
Results availability: 0/5
Program risk: 4/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT05162118
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT05162118 | Unknown Status Signal (UNKNOWN) | stale_update_signal | primary_completion_date_past_signal | completion_date_past_signal | Low Signal | rare_population_signal | strict_eligibility_signal |